trending Market Intelligence /marketintelligence/en/news-insights/trending/eKqLcWSLQ3S0uh8rHK88AA2 content esgSubNav
In This List

Dechra Pharmaceuticals adds director

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Dechra Pharmaceuticals adds director

Dechra Pharmaceuticals PLC appointed Lisa Bright to the board as a nonexecutive director, effective Feb. 1, 2019.

Bright serves on the board of Ascendis Pharma A/S and has been president, international, at Intercept Pharmaceuticals Inc. since July 2016. She was also previously a vice president at GlaxoSmithKline PLC and Gilead Sciences Inc.

Northwich, U.K.-based Dechra Pharmaceuticals develops veterinary pharmaceuticals and related products for veterinarians worldwide.